TwoStep Therapeutics, Inc. competitors & alternatives

TESSELLATE THERAPEUTICS INCBiotechnologyUnited States

67% matchPrivate

Biotechnology

Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.

T3 Pharmaceuticals AGBiotechnologySwitzerland

66% match

Biotechnology

T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.

Similar biotech company

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.

Laigo BioBiotechnologyNetherlands

65% match

Biotechnology

Laigo Bio is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary SureTAC platform. The company utilizes bispecific antibodies to direct cell surface targets toward lysosomal degradation, primarily serving the oncology and immunology sectors.

VALERIO TXALVIO · BiotechFrance

65% matchPublic

Similar biotech company

Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.

ADAPTIN BIO, INC.APTN · BiotechUnited States

65% matchPublic

Similar biotech company

Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.

IpiNovyx Bio, Inc.BiotechnologyUnited States

65% matchPrivate

Biotechnology

IpiNovyx Bio, Inc. is a biopharmaceutical company that discovers and develops targeted proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Utilizing a proprietary technology platform, the company focuses on advancing selective and reversible immunoproteasome inhibitors to create safer and more effective therapies for patients.

Xanadu Bio, Inc.BiotechnologyUnited States

65% match

Biotechnology

Xanadu Bio, Inc. is a biotechnology company that develops next-generation polymer nanoparticle delivery platforms for mRNA and other nucleic acid-based therapies. Utilizing its proprietary poly(amine-co-ester) (PACE) polymer technology, the company creates tunable, organ-specific treatments for oncology and immunology, as well as intranasal vaccines for viral respiratory pathogens.

BIND TherapeuticsBiotechnologyUnited States

64% match

Biotechnology

BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.

Silverback TherapeuticsBiotechnologyUnited States

64% match

Biotechnology

Silverback Therapeutics, Inc. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop therapeutic products.

Biotechnology

Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.

Similar biotech company

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.